Serum copper and zinc measurements in patients with osteogenic sarcoma

D. N. Breiter, Robert B Diasio, J. P. Neifeld, M. L. Roush, S. A. Rosenberg

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Serum copper level (SCL), serum zinc level (SZL), and SCL/SZL ratio were measured in 18 patients with biopsy-proven osteogenic sarcoma. Measurements were made on sequentially collected serum samples beginning prior to the institution of therapy and continuing periodically until documented relapse. All patients were treated by curative resection and adjuvant therapy consisting of high dose methotrexate (with leucovorin rescue) with or without BCG immunotherapy. The SCL, SZL, and SCL/SZL determinations were made using proton-induced x-ray fluorescence spectrometry. SCL was significantly elevated (p<.0001) in the 18 patients with primary untreated osteogenic sarcoma (173±30 μg/dl) compared with a sex and age-matched normal group (115±16 μg/dl). A significantly different SZL was not found, however, so that an elevated SCL/SZL ratio in the osteogenic sarcoma patients was primarily due to the altered SCL. SCL and SCL/SZL did not change significantly following curative surgery or become more abnormal in those patients who developed recurrent disease. The SCL and SCL/SZL were noted to be markedly elevated in those patients receiving BCG therapy, thus raising concern regarding the specificity of these tests as markers of tumor activity. SCL, SZL, and SCL/SZL did not appear useful as markers of tumor activity in patients with osteogenic sarcoma.

Original languageEnglish (US)
Pages (from-to)598-602
Number of pages5
JournalCancer
Volume42
Issue number2
StatePublished - 1978
Externally publishedYes

Fingerprint

Osteosarcoma
Zinc
Copper
Serum
Tumor Biomarkers
Mycobacterium bovis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Breiter, D. N., Diasio, R. B., Neifeld, J. P., Roush, M. L., & Rosenberg, S. A. (1978). Serum copper and zinc measurements in patients with osteogenic sarcoma. Cancer, 42(2), 598-602.

Serum copper and zinc measurements in patients with osteogenic sarcoma. / Breiter, D. N.; Diasio, Robert B; Neifeld, J. P.; Roush, M. L.; Rosenberg, S. A.

In: Cancer, Vol. 42, No. 2, 1978, p. 598-602.

Research output: Contribution to journalArticle

Breiter, DN, Diasio, RB, Neifeld, JP, Roush, ML & Rosenberg, SA 1978, 'Serum copper and zinc measurements in patients with osteogenic sarcoma', Cancer, vol. 42, no. 2, pp. 598-602.
Breiter DN, Diasio RB, Neifeld JP, Roush ML, Rosenberg SA. Serum copper and zinc measurements in patients with osteogenic sarcoma. Cancer. 1978;42(2):598-602.
Breiter, D. N. ; Diasio, Robert B ; Neifeld, J. P. ; Roush, M. L. ; Rosenberg, S. A. / Serum copper and zinc measurements in patients with osteogenic sarcoma. In: Cancer. 1978 ; Vol. 42, No. 2. pp. 598-602.
@article{092a9744776e41789678510690d15e0d,
title = "Serum copper and zinc measurements in patients with osteogenic sarcoma",
abstract = "Serum copper level (SCL), serum zinc level (SZL), and SCL/SZL ratio were measured in 18 patients with biopsy-proven osteogenic sarcoma. Measurements were made on sequentially collected serum samples beginning prior to the institution of therapy and continuing periodically until documented relapse. All patients were treated by curative resection and adjuvant therapy consisting of high dose methotrexate (with leucovorin rescue) with or without BCG immunotherapy. The SCL, SZL, and SCL/SZL determinations were made using proton-induced x-ray fluorescence spectrometry. SCL was significantly elevated (p<.0001) in the 18 patients with primary untreated osteogenic sarcoma (173±30 μg/dl) compared with a sex and age-matched normal group (115±16 μg/dl). A significantly different SZL was not found, however, so that an elevated SCL/SZL ratio in the osteogenic sarcoma patients was primarily due to the altered SCL. SCL and SCL/SZL did not change significantly following curative surgery or become more abnormal in those patients who developed recurrent disease. The SCL and SCL/SZL were noted to be markedly elevated in those patients receiving BCG therapy, thus raising concern regarding the specificity of these tests as markers of tumor activity. SCL, SZL, and SCL/SZL did not appear useful as markers of tumor activity in patients with osteogenic sarcoma.",
author = "Breiter, {D. N.} and Diasio, {Robert B} and Neifeld, {J. P.} and Roush, {M. L.} and Rosenberg, {S. A.}",
year = "1978",
language = "English (US)",
volume = "42",
pages = "598--602",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Serum copper and zinc measurements in patients with osteogenic sarcoma

AU - Breiter, D. N.

AU - Diasio, Robert B

AU - Neifeld, J. P.

AU - Roush, M. L.

AU - Rosenberg, S. A.

PY - 1978

Y1 - 1978

N2 - Serum copper level (SCL), serum zinc level (SZL), and SCL/SZL ratio were measured in 18 patients with biopsy-proven osteogenic sarcoma. Measurements were made on sequentially collected serum samples beginning prior to the institution of therapy and continuing periodically until documented relapse. All patients were treated by curative resection and adjuvant therapy consisting of high dose methotrexate (with leucovorin rescue) with or without BCG immunotherapy. The SCL, SZL, and SCL/SZL determinations were made using proton-induced x-ray fluorescence spectrometry. SCL was significantly elevated (p<.0001) in the 18 patients with primary untreated osteogenic sarcoma (173±30 μg/dl) compared with a sex and age-matched normal group (115±16 μg/dl). A significantly different SZL was not found, however, so that an elevated SCL/SZL ratio in the osteogenic sarcoma patients was primarily due to the altered SCL. SCL and SCL/SZL did not change significantly following curative surgery or become more abnormal in those patients who developed recurrent disease. The SCL and SCL/SZL were noted to be markedly elevated in those patients receiving BCG therapy, thus raising concern regarding the specificity of these tests as markers of tumor activity. SCL, SZL, and SCL/SZL did not appear useful as markers of tumor activity in patients with osteogenic sarcoma.

AB - Serum copper level (SCL), serum zinc level (SZL), and SCL/SZL ratio were measured in 18 patients with biopsy-proven osteogenic sarcoma. Measurements were made on sequentially collected serum samples beginning prior to the institution of therapy and continuing periodically until documented relapse. All patients were treated by curative resection and adjuvant therapy consisting of high dose methotrexate (with leucovorin rescue) with or without BCG immunotherapy. The SCL, SZL, and SCL/SZL determinations were made using proton-induced x-ray fluorescence spectrometry. SCL was significantly elevated (p<.0001) in the 18 patients with primary untreated osteogenic sarcoma (173±30 μg/dl) compared with a sex and age-matched normal group (115±16 μg/dl). A significantly different SZL was not found, however, so that an elevated SCL/SZL ratio in the osteogenic sarcoma patients was primarily due to the altered SCL. SCL and SCL/SZL did not change significantly following curative surgery or become more abnormal in those patients who developed recurrent disease. The SCL and SCL/SZL were noted to be markedly elevated in those patients receiving BCG therapy, thus raising concern regarding the specificity of these tests as markers of tumor activity. SCL, SZL, and SCL/SZL did not appear useful as markers of tumor activity in patients with osteogenic sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=0018191989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018191989&partnerID=8YFLogxK

M3 - Article

C2 - 307981

AN - SCOPUS:0018191989

VL - 42

SP - 598

EP - 602

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -